Sanofi suffers a diabetes bloodbath as Medicare and price cuts compound the formulary pain
admin 27th April 2018 Uncategorised 0Formulary shutouts were already hurting Sanofi’s diabetes numbers. But this quarter, price cuts and Medicare changes deepened the wounds, and the company’s newcomers Praluent and Dupixent fell short of expectations as well. Better-than-expected earnings weren’t much of a salve. The CEO’s pledge? A return to growth in the second half.
More: Sanofi suffers a diabetes bloodbath as Medicare and price cuts compound the formulary pain
Source: fierce